Phase 3 Readout
NVO: Phase 3 Topline: Efficacy and Safety of Cagrilintide s.c. 2.4 Milligram (mg) in Combination With Semaglutide Subcutan
October 19, 2026 · semaglutide. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- October 19, 2026
- Company
- Novo Nordisk A/S (NVO)
- Drug
- semaglutide
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: Efficacy and Safety of Cagrilintide s.c. 2.4 Milligram (mg) in Combination With Semaglutide Subcutan
- Company
- Novo Nordisk A/S (NVO)
- Drug
- semaglutide
- Indication
- Obesity